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Osteoporosis is characterized by increased bone turnover, low
bone mass and an increased risk of fracture. The bone loss results
from an imbalance between bone resorption and formation.
Osteoporosis continues to be a major health problem.
Approximately 200 million adults worldwide have osteoporosis [1,
2], and approximately 30% of all postmenopausal women in the
Europe and the USA have osteoporosis [3]. Notwithstanding the
availability of effective treatments for osteoporosis, such as the bis-
phosphonates (alendronate, risedronate, ibandronate and zole-
dronate), estrogen-based therapies, selective estrogen receptor
modulators (raloxifene and bazedoxifene), parathyroid hormone
and other niche treatments, including vitamin D derivatives and
strontium (in some countries), many individuals with osteoporosis
remain untreated. Although many individuals with osteoporosis
remain undiagnosed, this lack of treatment may also reflect poor
tolerability and mechanism-based toxicities of current therapies for
osteoporosis. New therapies for osteoporosis that may potentially
improve or augment existing therapies include the recently approved
anti-Receptor Activator of NF-KappaB-ligand monoclonal anti-
body (denosumab/Prolia) and the cathepsin K (CatK) inhibitor
odanacatib (ODN), presently in late stage clinical development.
Cells involved in bone remodeling: 
osteoblasts and bone formation 
Bone is a dynamic tissue that undergoes continual adaption
during life to attain and preserve skeletal size, shape and structur-
al integrity and regulate mineral homeostasis. Two processes,
remodeling and modeling, underpin development and mainte-
nance of the skeletal system. Bone modeling is responsible for
growth and mechanically induced adaption of bone and requires
that the process of bone formation and bone resorption, while
globally coordinated, occur independently at distinct anatomical
location. This tightly coordinated event requires the synchronized
activities of multiple cellular participants to ensure bone resorp-
tion and formation occur sequentially at the same anatomical
location to preserve bone mass. Bone remodeling is a physiologi-
cal process that maintains the integrity of the skeleton by remov-
ing old bone and replacing it with a young matrix. Two principle
cell types are found in bone, the osteoclast, and the osteoblast,
which are the major effectors in the turnover of bone matrix (Fig. 1)
[4, 5]. Osteoblasts and osteoclasts dictate skeletal mass, structure,
and strength via their respective roles in resorbing and forming
bone. Osteoblasts are specialized mesenchymal-derived cells
С О В P E М Е Н Н А Я  Р Е В М А Т О Л О Г И Я  № 2 ’ 1 6
О Б З О Р Ы
56
The article presents review of literature dedicated to the contemporary view on the cellular-molecular mechanisms of the bone remodeling and
pathogenesis of the osteoporosis. The discovery of the cytokine RANKL-RANK-OPG system and significant role of the cathepsin K in process
bone remodeling has made progress in understanding the mechanisms development disease and possible to development drugs of the new gen-
eration – denosumab, a fully human RANKL monoclonal antibody and inhibitor cathepsin K odanacatib that inhibits of the bone resorption.
Key words: osteoporosis, RANKL-RANK-OPG-signaling pathway; cathepsin K; denosumab; odanacatib.
Contact: Stanislav Sagalovsky; s.sagalovsky@gmail.com
For reference: Dolzhenko AT, Sagalovsky S. Cellular and molecular mechanisms of osteoporosis: current concepts and future direction treat-
ment. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2016;10(2):56–63.
DOI: http://dx.doi.org/10.14412/1996-7012-2016-2-56-63
Клеточно-молекулярные механизмы развития остеопороза: современные концепции и будущее направление терапии 
Долженко А.Т.1, Сагаловски С.2
1Институт молекулярной медицины, Университет им. Мартина Лютера Галле-Виттенберг, Германия; 
2Отдел ортопедии клиники Медиан, Бад Лаузик, Германия
В обзоре литературы представлены современные взгляды на клеточно-молекулярные механизмы развития ремоделирования кости
и патогенез остеопороза. Открытие цитокиновой системы RANKL-RANK-OPG и значительной роли катепсина К в процессе ре-
моделирования костной ткани способствовало значительному прогрессу в понимание механизмов развития остеопороза и позво-
лило разработать препараты нового поколения – деносумаб, полностью человеческое моноклональное антитело к RANKL (recep-
tor activator nucleus factor kappa B ligand), и ингибитор катепсина К оданакатиб, угнетающие процесс резорбции костной ткани.
Ключевые слова: остеопороз; RANKL-RANK-OPG-сигнальный путь; катепсин К; деносумаб; оданакатиб.
Контакты: Станислав Сагаловски; s.sagalovsky@gmail.com
Для ссылки: Долженко АТ, Сагаловски С. Клеточно-молекулярные механизмы развития остеопороза: современные концепции и бу-
дущее направление терапии. Современная ревматология. 2016;10(2):56–63.
C e l l u l a r  a n d  m o l e c u l a r  m e c h a n i s m s  o f
o s t e o p o r o s i s :  c u r r e n t  c o n c e p t s  a n d  f u t u r e
d i r e c t i o n  t r e a t m e n t
Dolzhenko A.T.1, Sagalovsky S.2
Biomedical Research Unit, Institute of Molecular Medicine Martin-Luther University Halle-Wittenberg, Germany1
Department of Orthopedics Median Clinic2, Bad Lausick, Germany
С О В P E М Е Н Н А Я  Р Е В М А Т О Л О Г И Я  № 2 ’ 1 6
О Б З О Р Ы
57
whose function is the deposition and maintenance of skeletal tis-
sue. Osteoblasts derive from pluripotent mesenchymal stem cells
(MCS) that prior to osteoblast commitment can also differentiate
into other mesenchymal cells lineages such as fibroblasts, chon-
drocytes, myoblasts and bone marrow stromal cells including
adipocytes, depending on the activated signaling transcription
pathways. Understanding the mechanisms that control the differ-
entiation of osteoblastic cells from MCS is thus one of the funda-
mental areas of research of bone biology. Several specific tran-
scription factors are responsible for the commitment of pluripo-
tent MSC into the osteoblast cell lineage [6]. Lineage-specific
gene expression is ultimately under the control of transcription
factors that act to regulate specifi c gene expression. They act as
the key switching mechanisms to induce gene transcription.
Considerable progress has been made in identifying those tran-
scription factors which act as «master switches» during commit-
ment of multipotent cells to specific lineages. A major break-
through in understanding genetic regulation of osteoblast differ-
entiation was made with the identification of the role of the tran-
scription factor core binding factor 1 (Cbfa-1/RUNX-2) [7, 8].
Cbfa-1/RUNX-2 expression is an absolute requirement for
osteoblast differentiation. In Cbfa-1 knockout mice there is a
normal cartilaginous skeleton seen but a complete absence of
bone formation [9]. Cbfa-1/RUNX-2 known to interact directly
with the osteocalcin promoter to induce its expression [10].
However an additional transcription factor, Osterix, which is a
downstream target for Cbfa1/RUNX-2, has also been shown to
be an absolute requirement for normal osteoblast differentiation
in knockout mice experiments [11]. More recent studies have
shown the existence of distinct isoforms of Cbfa-1, which may
have subtly different roles during normal tissue formation,
including regulation of cartilage expression in addition to bone.
Another runt-related gene that plays an important role in the
commitment of multipotent MSC to the 1/RUNX-2, has also
been shown to be an absolute requirement for normal osteoblast
differentiation in knockout mice experiments [11]. More recent
studies have shown the existence of distinct isoforms of Cbfa-1,
which may have subtly different roles during normal tissue forma-
tion, including regulation of cartilage expression in addition to
bone. Another runt-related gene that plays an important role in
the commitment of multipotent MSC to the osteoblastic lineage
and for osteoblast differentiation at an early stage is RUNX-2.
Cbfa-1/RUNX-2 are involved in the production of bone matrix
proteins [12], as it is able to up-regulate the expression of major
bone matrix protein genes, such as type I collagen, osteopontin,
bone sialoprotein and osteocalcin leading to an increase of imma-
ture osteoblasts from MCS; the immature osteoblasts from
immature bone [13]. Osteoblast commitment, differentiation and
growth are controlled by several local and systemic factors that
can also act in a paracrine and/or autocrine way and that can reg-
ulate the activity of specific transcription factor [14]. Huge
advances have been made in the understanding of cellular and
molecular control of bone formation in the past decade. The
establishment of in vitro models of osteoblast differentiation and
formation has been essential for determining the effects of specif-
ic growth factors and growth factor-induced transcription factors
on osteogenesis. Osteoblasts play a crucial role in the process of
bone formation, in the induction and regulation of extracellular
matrix mineralization and in the control of bone remodeling [15].
During bone formation, mature osteoblasts synthesize and
secrete type I collagen (which represents the greated part of the
organic extracellular bone matrix) and various non-collagen pro-
teins such as osteocalcin, osteopontin and bone sialoprotein
(which exert various essential functions, including the regulation
of bone turnover, the control of bone mineral deposition and reg-
ulation of bone cell activity). Osteocalcin (Gla) is a vitamin-K-
dependent osteoblast-specific protein and whose synthesis is
enhanced by 1,25 OH vitamin D3 and reflects metabolic cellular
activity. Of the de novo synthesized osteocalcin, 60–90% is incor-
porated into the bone matrix where it binds to hydroxyapatite
during matrix mineralization. Osteopontin (OPN) is a phospho-
rylated acidic glycoprotein that is present in large amounts in
immature bone. OPN is synthesized by osteoblast but is expressed
by other cellular types, such as chondrocytes; it is involved in var-
ious physiological and pathological events. Bone sialoproteins I
glycosylated, phosphorylated and sulfated protein that promotes
hydroxyapatite crystal nucleation and osteoblast differentiation
[16]. This has been confirmed by the observation that bone-sialo-
Fig. 1. RANKL–RANK–OPG system and regulation of osteoclast
precursor by osteoblast (A, B) and mechanisms of osteoclastic bone
resorption (C). Under physiologic condition, RANKL produced by
osteoclasts binds to its receptor RANK on the surface of osteoclast
precursors and recruits the adaptor protein TRAF6, leading to NF-
kB activation and translocation to the nucleus. NF-kB increases c-
Fos expression and c-Fos interacts with NFATc1 to trigger the
transcription of osteoclastogenic genes. OPG inhibits the initiation
of the process by binding to RANKL . The mechanisms of osteo-
clastic bone resorption (C): several transport systems including the
H+-ATPase proton pump, Cl-/HCO3 exchanger and chloride chan-
nel are responsible for the acidification in the osteoclastic resorp-
tion lacune. The osteoclast attaches to bone, which promts forma-
tion of a convoluted ruffl ed membrane and a resorptive microenvi-
ronment beneath the cell. Hydrocarbonic acid, the product of a
vacuolar-type H+-ATPase and charge-coupled CL channel con-
centrated in the ruffled membrane, is secreted, resulting in mineral
dissolution. Vesicles containing acidic collagenolytic enzymes in the
form of cathepsins K, fuse with the bone-apposed membrane, lead-
ing matrix degradation. Intracellular pH balance is maintained by
a passive Cl-/HCO3- exchanger on the contraresorptive surface of
the cell. In the right corner: this fi gure summarized current infor-
mation and hypotheses regulating the role of avβ3-integrin in osteo-
clast formation, adhesion, polarization and migration. The natural
ligand for avβ3-integrin is not known, however osteopontin and
bone sialoprotein are two RGD (arginine-glycine-aspartate) con-
taining proteins which could potentially be ligandes. See text for
future details. Abbreviations: NFATc1, nuclear factor of activated
T cells; NF-kB, nuclear factor- kB; OPG, osteoprotegerin;
RANKL, receptor activator of nuclear factor-kB ligand; TRAF, tu-
mor necrosis factor receptor associated factor 
protein-knockout mice present hypo-mineralized bone, a reduc-
tion in the size of their long bones and aberrant levels of osteoblast
markers [17]. Osteoblasts also synthesize cytokine interleukin-1
(IL-1) and interleukin-6 (IL-6), which control bone cells in an
autocrine and/or paracrine manner. Various in vitro studies of
human and murine osteoblastic cell lines suggest that IL-1 can
affect proliferation, collagen and osteocalcin synthesis and alka-
line phosphatase production [18]. Osteoblasts express receptors
for various hormones including parathyroid hormone (PTH)
[19], 1,25 (OH)2D3 [20], estrogenes [21], which are involved in
the regulation of osteoblast differentiation and activity. Vitamin
D3 is able to modulate the metabolic activity of osteoblasts
through the activation of a series of Vitamin- D-responsive genes
that reflect a more mature osteoblast phenotype.
Control of bone remodeling by osteoblasts: the role
RANKL–RANK–OPG system of the osteoclast development
In recent years it has become evident that osteoblasts have a
global role in orchestrating the bone remodeling process. Their
function is not restricted solely to bone formation, but it is now
firmly established that they are responsible for initiating bone
resorption. In cellular terms, apart from forming the mineral and
organic extracellular compartment of bone, the osteoblast pro-
vides the essential and sufficient stimuli that control the behavior
of the osteoclast, an event that occurs via cell-cell interaction.
The bone resorption cascade involves a series of steps directed
towards the removal of both the mineral and organic constituents
of bone matrix by osteoclasts, aided by osteoblasts (Fig. 1). The
role of the osteoclast as a major resorbing cell, and its structure
and biochemical properties have been well characterized [22, 23].
The first stage involves the recruitment and dissemination of
osteoclast progenitors to bone. The progenitor cells are recruited
from the haemopoietic tissue such as bone marrow and slenic tis-
sue to bone via the circulating blood stream. They proliferate and
differentiate into osteoclasts through a mechanism involving cell-
to-cell interaction with osteoblast stromal cells. Osteoclast for-
mation from osteoclast precursor is regulated predominantly by
osteoblastic cells during normal bone remodeling. Osteoblastic
cells in the bone marrow express two cytokines that are required
for osteoclast-progenitor differentiation into osteoclasts: receptor
activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG)
[24] (Fig. 1, A). The discoveries of the receptor activator of NF-
kB ligand and osteoprotegerin have revolutionized our under-
standing of the process underlying osteoclast formation and acti-
vation [25, 26]. RANKL and OPG potently stimulate and inhib-
it, respectively, osteoclast differentiation. RANKL is a membrane
bound factor that is produced by osteoblasts and stromal cells in
response to a variety of signals such as parathyroid hormone
(PTH), tumor necrosis factor-α (TNF-α) and Il-1. RANKL bind
to the cytoplasmic membrane receptor RANK (receptor activator
of NF-kB), which is a member of the tumor necrosis factor
(TNF) receptor super family and subsequently induces both
osteoclast differentiation and activation. OPG is a soluble decoy
receptor for RANKL and can inhibit its effects, thereby prevent-
ing osteoclast development and subsequent bone resorption [27].
Over expression of OPG in transgenic mice results in osteopetro-
sis, and, conversely, OPG deficient mice exhibit severe osteo-
porosis. Many of the same agent that stimulate RANKL expres-
sion (including PTH, IL-1, PGE) also inhibit OPG expression
[28, 29], which enhances osteoclastogenesis even further. While
FGF-2 induces RANKL expression by osteoblasts, it also inhibits
osteoclast differentiation directly by interfering with the action of
macrophage colony stimulating factor (M-CSF) [30]. In con-
trast, to the stimulatory effects of the agents described above,
estrogen inhibits the production of RANKL by osteoblasts [31].
Transforming growth factor-β (TGF-β) also strongly suppresses
RANKL expression by osteoblasts, whereas it stimulates OPG
expression [32]. Administration of RANKL to mice causes osteo-
porosis, whereas disruption of the RANKL gene in mice leads to
severe osteopetrosis, impaired tooth eruption, and the absence of
osteoclasts [33]. Membrane bound macrophage colony stimulat-
ing factor (M-CSF) is also a critical early modulator in the dif-
ferentiation of osteoclasts [34]. M-CSF binds to c-Fms on the
surface of osteoclast precursors, and this event enhances their
proliferation and survival. M-CSF enhances the survival of
monocyte stem cells thereby permitting them to respond to direct
inducers of differentiation such as RANKL. A combination of M-
CSF and RANKL is sufficient for human, mouse, and rat multi-
nucleated osteoclast formation in vitro (Fig. 2, b) [34]. Although
RANKL is critical for osteoclast formation and activation, a
series of complementary studies has revealed a number of addi-
tional gene products that are necessary for osteoclastogenesis and
a variety of hormones and cytokines that modulate osteoclast for-
mation [23, 35]. Deletion of the genes for M-CSF, c-fos, RANK
and NF-kB results in absent osteoclast formation confirming
their requirement for osteoclastogenesis. Osteoclasts are formed
in mice whom the genes for TRAF6 (TNF receptor activating
factor 6) and the c-fos have been deleted; however, these osteo-
clasts exhibit defects in bone resorption resulting in osteopetrosis
[36]. Interestingly, another TRAF6 knockout mice exhibits
defective osteoclastogenesis. TRAF6 activates the MAP kinase
cascade, and eventually activates JNK, JKK and N-kB have been
directly implicated in the response to RANKL [37] (Fig. 1, b).
Different domains of TRAF6 modulate both the initial differen-
tiation and subsequent maturation of osteoclasts by activating
various kinase cascades. RANKL also activates NF-kB in osteo-
clasts , in large part via TRAF stimulation of Ik kinase (IKK) to
phosphorylate IkB, which then dissociates from NF-kB, and per-
mits NF-kB translocation into the nucleus and subsequent bind-
ing to NF-kB responsive genes. TNF-α also acts to induce osteo-
clast formation and activation in concert with RANKL via the
TNF receptor and TRAF2/6 and subsequently to activate NF-kB
signaling [38].
Osteoclast and bone resorption
The development of an in vitro bone resorption model using
isolated primary  osteoclasts and mineralized bone matrix as a
substrate almost twenty years ago provided an excellent system for
detailed cell biological studies of bone resorption [39]. Although
this model has several limitations in attempts to study the whole
physiological cascade of bone resorption, it provides an excellent
tool for detailed studies of the cellular mechanisms involved in
the destruction of mineralized bone matrix. The sequence of cel-
lular events needed for bone resorption is called the resorption
cycle. Resorption requires cellular activates : migration of the
osteoclast to the resorption site, its attachment to bone, polariza-
tion and formation of new membrane domains, dissolution of
hydroxyapatite, degradation of organic matrix, removal of degra-
dation products from the resorption lacuna, and finally either
apoptosis of the osteoclasts or their return to the nonresorbing
stage (Fig. 1, C). The term resorption cycle covers neither the dif-
ferentiation pathway nor the cellular activities needed for the
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fusion of mononuclear precursor to form the multinuclear mature
osteoclast. It should not be mistaken for the more widely used
term remodeling cycle, which is used to describe the bone remod-
eling at the tissue level that involves the activities of several differ-
ent cell types. After migration of the osteoclast to a resorption
site, a specific membrane domain, the sealing zone, forms under
the osteoclast. The plasma membrane attached tightly to the bone
matrix and seals the resorption site form its surroundings .The
molecular interactions between the plasma membrane and the
bone matrix at the sealing zone is still unknown. Several lines of
evidence have shown, however, that integrins play an important
role in early phases of the resorption cycle [40]. At last four dif-
ferent integrins are expressed in osteoclasts: αvα3, αvα5, α2β1 and
αvβ1 [40, 41]. The role of αvβ3 has received much attention,
because antibodies against αvβ3, as well as argynine-glycine-
aspartic acid (RGD)-containing peptides such as echistation and
kistrin, are defective inhibitors of bone resorption both in vitro
and in vivo [41]. αvβ3 is highly expressed in osteoclasts and is
found but what the plasma membrane and in various intracellular
vacuoles. However, the precise function of αvβ3 in resorbing
osteoclasts remains unknown; the integrin could play a role both
in adhesion and migration of osteoclasts and in endocytosis of
resorption products. The latter possibility is supported by the
observation that high amount of αvβ3 are present at the ruffled
border and by recent data from receptor-binding assays showing
that denatured type I collagen has a high affinity for αvβ3. Some
authors have suggested that αvβ3 integrin also mediates the
attachment of the sealing zone to the bone matrix [41]. Previous
ultrastructural studies indicated that resorbing osteoclasts are
highly polarized cells. Current data suggest that resorbing osteo-
clasts contain not only the sealing zone but also at least three
other specialized membrane domains: a ruffled border, a func-
tional secretary domain and a basolateral membrane [42]. As the
osteoclast prepares to resorb bone, it attaches to the bone matrix
through the sealing zone and forms another specific membrane
domain, the ruffled border. The ruffled border is a resorbing
organelle, and it is formed by fusion of intracellular acidic vesicles
with the region of plasma membrane facing the bone [42]. During
this fusion process much internal membrane is transferred, and
forms long, finger-like projections that penetrate the bone matrix.
The characteristics of the ruffled border to not match those of any
other plasma membrane domain described. Although facing the
extracellular matrix, it has several features that are typical of late
endosomal membranes. Several late endosomal markers, such as
CIC-7, V-type H+-ATPase, are densely concentrated at the ruf-
fled border [43]. The main physiological function of osteoclast is
degrading mineralized bone matrix. This involves dissolution of
crystalline hydroxyapatite and proteolytic cleavage of the organic
matrix, which is rich in collagen. Before proteolytic enzymes can
reach and degrade collagenous bone matrix, tightly packed
hydroxyapatite crystals must be dissolved. It is now generally
accepted that the dissolution of mineral occurs by targeted secre-
tion of HCl through the ruffled border into the resorption lacuna.
This is an extracellular space between the ruffled border mem-
brane and the bone matrix, and is sealed from the extracellular
fluid by the sealing zone. The low pH in the resorption lacuna is
achieved by the action of ATP-consuming vacuolar proton pumps
both at the ruffled border membrane and in intracellular vacuoles.
Osteoclasts attach to bone and form a circumferential sealing
zone that isolates the bone resorption compartment from the
extracellular space. Osteoclast plasma membrane within the seal-
ing zone develops into the ruffled border. The observation that
NH4Cl reversibly inhibits bone resorption by osteoclasts indicates
that the resorption compartment is acidic and that the sealing
zone is impairment to H+ and NH+4. The osteoclast cytoplasm is
rich in carbonic anhydrase [25, 44], proving a continuous supply
of protons and bicarbonate. Protons are transported across this
membrane into the bone resorption compartment by vacuolar-
type H+-ATPase (V-type ATPase). Chloride ions passively follow
the protons through conductive anion channels. The combined
activities of the proton pump and chloride channel acidify the
resorption compartment and alkalinize the cytoplasm.
Bicarbonate exits the cell into the extracellular space in exchange
for chloride via a basolateral electroneutral anion exchanger, cor-
recting the cytoplasmic alkalinization and compensating for
cytoplasmic chloride loss. The net result of these coordinated
transport activities is the transcellular movement of HCl into the
bone resorption compartment. This model predicts that both the
ruffled border proton pump and chloride channel play key roles in
bone resorption. The proton pump provides the proton-motive
force necessary to generate a pH gradient. However, the pump is
electrogenic. The chloride channel shot-circuits the electrogenic
pump and allows maximal proton transport. It follows that limi-
tation of the chloride conductance could inhibit acid transport
independently of the intrinsic activity of the proton pump.
Analogous to a current model for regulation of the pH of some
intracellular organelles, regulation of the anion conductance
rather than proton pump activity could be the key point at which
the rate of osteoclast acid transport, and hence bone resorption,
is governed. Thus, molecular characterization of the ruffled bor-
der chloride channel may provide insight into regulation of osteo-
clast bone resorption and could define a pharmacological target
for the treatment of metabolic bone disease. The osteoclast pro-
ton pump is sensitive to bafilomycin A1, which also effectively
inhibits bone resorption both in vitro and in vivo. The recent find-
ing that vacuolar ATPase at the ruffled border contains cells spe-
cific subunits has further encouraged development of resorption
inhibitors that inhibit the osteoclast proton pump. Protons for the
proton pump are produced by cytoplasmic carbonic anhydrase II,
high levels of which are synthesized in osteoclasts. In order to
generate protons, the presence of carbonic anhydrase II (CA II)
is essential. It catalyzes the conversion of H2O and CO2 into
H2CO3, which then is ionized into H+ and HCO-3. Mutation in
CA II can cause osteopetrosis due to non-functional osteoclasts
[45]. The HCO-3 ions are exchanged for Cl- through an anion
exchanger, membrane transport protein AE2, located in the baso-
lateral membrane, leading to continued of Cl- for acidification of
the resorption lacuna. After solubilization of the mineral phase,
several proteolytic enzymes degrade the organic bone matrix,
although the detailed sequence of events at the resorption lacuna
is still obscure. Two major classes of proteolytic enzymes, lysoso-
mal cysteine proteinases and matrix metalloproteinases (MMPs)
have been studied most extensively. Osteoclasts produce proteas-
es, of which cysteine proteinase cathepsin K has prevent to be the
most important [46], aiding the degradation of the organic bone
matrix. Eleven different types have been described (B, C, F, H, K,
L and other) with cathepsin K being the most important with
respect to bone remodeling, since it is a protease with intense col-
lagenase activity, especially with respect to acid pH, which is
essential to dissolve calcic hydroxyapatite, the main mineral com-
ponent of bone. It degrades the two types of collagen, I and II and
is predominantly expressed in osteoclasts. Cathepsin K gives rise
to specific degradation products-like C-terminal cross-linking
telopeptide of type I collagen (CTX-I), which can be used for
measurements of bone resorption [46]. The role of cathepsin K in
bone resorption was determined using evidence from an autoso-
mal recessive osteochondrodysplasia named pycnodysostosis, a
very rare disease characterized by high bone mineral density,
acroosteolysis of the distal phalanxes, shot stature, and cranial
deformaties with late closing of the fontanelles [47]. Studies in
mice submitted to nonfunctional mutations of cathepsin have
given rise to different models of osteopetrosis. Matrix in bone
resorption, during which, MMP activity is known to give rise to a
specific degradation fragment, C-terminal telopeptide of type I
collagen (ICTP) [46]. After matrix degradation, the degradation
products are removed from the resorption lacuna through a tran-
scytotic vascular pathway from the ruffled border to the function-
al secretory domain, where they are liberated into the extracellu-
lar space. Quantitative data are still missing, but clear large
amounts of degraded extracellular material must be transported
through the resorbing cell, given that the volume of the resorption
pit can easily exceed the volume of the entre cell. The extent to
which the degradation of collagen and other matrix components
is extracellular and the extent to which this takes place in intra-
cellular transcytotic compartments are not known. Recent results
have suggested that tartrate-resistant acid phosphatase (TRAP), a
widely used osteoclast marker, is licalized in the transcytotic vesi-
cles of resorbing osteoclasts, and that it can generate highly
destructive reactive oxygen species able to destroy collagen. This
activity, together with the co-localization of TRAP and collagen
fragments in transcytotic vesicles, suggests that TRAP functions
in further destruction of matrix-degradation products in the tran-
scytotic vesicles. The observed mild osteopetrosis in TRAP-
knockout mice support this hypothesis [48]. 
New therapeutic strategies for bone resorption inhibition
Currently available therapies for postmenopausal osteoporo-
sis either aim at correcting the estrogen deficit (HRT, SERM),
specifically target osteoclasts (calcitonon, bisphosphonates) or
stimulate bone formation (fluoride). Better understanding of the
molecular processes of bone remodeling [4, 23] has led to the
development of agents to inhibits bone resorption, such as the
human monoclonal antibody – denosumab [49] and inhibitor
enzyme cathepsin K odenacatib [50].
RANKL-inhibitor denosumab
Denosumab, the first in class RANKL-inhibitor, is a recombi-
nant human IgG2 antibody with affinity and specificity for
RANKL. By binding to RANKL, denosumab prevents the
RANKL/RANK interaction on the osteoblast which leads to the
inhibition of osteoclast formation, function, and survival, thereby
decreasing bone resorption and increasing bone mass and strength
in both cortical and trabecular bone. The 3-year, randomized, dou-
ble-blind, placebo-controlled fracture endpoint trial FREEDOM
enrolled 7808 women between the ages of 60 and 90 years (mean 
72 years) who had a baseline BMD T-score between -2,5 and -4,0
at either the lumbar spine or total hip. The mean baseline lumbar
spine BMD T-score was -2,8 SD, and 23% of women had a verte-
bral fracture at baseline. Women were randomized to receive SC
injections of either placebo (N=3906) or denosumab 60 mg
(N=3902) once every 6 months. All women received at least 1000 mg
calcium and 400 IU vitamin D supplementation daily. Denosumab
significantly reduced the incidence of new morphometric vertebral
fractures (primary endpoint) at 3 years (7,2% vs 2,3% – 68%, 
p<0,0001). In addition, denosumab significantly reduced the inci-
dence of hip and non-vertebral fractures (secondary endpoints) at
3 years (1,2% vs 0,7% –  40%, p=0,04 and 8,0% vs 6,5% – 20%,
p=0,01, respectively) [51]. Furthermore, the antifracture efficacy
of denosumab was consistent across patients with varying degrees
of fracture risk. Denosumab was generally well tolerated. Based on
postmarketing and clinical research experience available to date,
denosumab exposes patients to a risk of hypocalcaemia, which is
significant in patients with severe renal impairment or receiving
dialysis, to a potential for adverse outcomes resulting from the
induced profound, even if reversible, suppression of bone remodel-
ling such as osteonecrosis of the jaw, atypical fractures and delayed
fracture healing, and to a potentially increased risk of severe infec-
tions consistent with its osteoimmunological effects. Epidermal
and dermal adverse events not specific to the injection site (such as
dermatitis, eczema, and rashes) were significantly increased.
Finally, cases of pancreatitis and new malignancies of the breast,
the reproductive system, and the gastrointestinal system were
numerically more frequent with denosumab with no established
causal relationship to drug exposure. Denosumab was also proven
effective for increasing BMD over 2 years in women receiving adju-
vant aromatase inhibitor therapy for breast cancer and for increas-
ing BMD and reducing the incidence of vertebral fractures over 3
years in men with non-metastatic prostate cancer receiving andro-
gen deprivation therapy. 
Cathepsin K inhibitor odanacatib
Odanacatib is the most advanced cathepsin K inhibitor cur-
rently under development. Odanacatib was shown to be orally
bio-available, highly selective for and reversibly binding to
cathepsin K [50, 52]. Based on phase I and II results, the recom-
mended dosage is 50 mg once weekly per os [53]. The increases in
spine and hip BMD observed with odanacatib were comparable to
those observed with the bisphosphonate zoledronate and the
RANKL-inhibitor denosumab [52]. The effect of odanacatib was
compared with placebo in a small phase III trial dedicated to
evaluating the effect of odanacatib with the latest bone imaging
techniques including QCT at the hip and lumbar spine (Fig. 2),
and high resolution peripheral (HRp) QCT at the distal radius
and tibia, along with the classical measures of areal BMD using
dual energy X-ray absorptiometry (DXA) and of biochemical
markers of bone turnover, among 214 postmenopausal with low
areal BMD. As early as 6 months, odanacatib-treated women had
greater increases in trabecular volumetric BMD and estimated
compressive strength at the spine compared with placebo; integral
and trabecular volumetric BMD and estimated strength at the hip
also improved. At the femoral neck cortex, bone mineral content,
thickness, volume and cross-sectional area also increased from
baseline with odanacatib versus placebo over the entire course of
the trial [54]. At the distal radius and tibia, total volumetric BMD
(vBMD), trabecular vBMD, cortical vBMD, cortical thickness
and strength estimated using FEA showed significantly greater
improvements with odanacatib compared with placebo. At the
hip, the trabecular and cortical compartment were similarly
affected by the gains in bone mineral content [55]. The magni-
tude of these microarchitectural evaluated the same way, although
no head-to-head comparison has been made.In another trial, the
effect of odanacatib taken after alendronate has been examined.
In this randomized, double-blind, placebo-controlled, 24-month
study, 243 postmenopausal women aged at least 60 years, with low
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BMD at the total hip, femoral neck or trochanter (T score ≤ -2,5
but > -3,5 without prior fracture or ≤ -1,5 but > -3,5 with prior
fracture) who had taken alendronate for ≥3 years were allocated
to receive odanacatib or placebo [54]. In the odanacatib group,
BMD changes from baseline at the femoral neck, trochanter,
total hip and lumbar spine at 24 months (1,7, 1,8, 0,8 and 2,3%,
respectively) were significantly different from the group switched
to placebo, but the variation at the radius did not differ signifi-
cantly between the two groups. As in prior reports of bisphospho-
nate-naÏve patients, urinary NTX decreased with odanacatib. The
level of beta CTX, however, increased unexpectedly. This might
be explained by predominantly metalloproteinase-mediated bone
resorption of older bone, which predominates in case of inhibi-
tion of CatK, while the inhibition of the resorption of younger
bone seemed to continue, as shown by reduced levels of alpha
CTX. The main outcome for registration of anti-osteoporosis
drugs is the another trial, the effect of odanacatib taken after alen-
dronate has been examined. reduction in fracture incidence. A
phase III trial – still unpublished and only presented in a sci-
entific meeting – involving 16,713 postmenopausal women
≥65 years of age with low BMD has been conducted to prove the
antifracture efficacy of odanacatib. Women were randomized to
receive weekly odanacatib 50 mg or placebo for 3 years. The pri-
mary outcomes were time to first morphometric (radiographical-
ly assessed) vertebral fracture, time to first hip fracture and time
to first hip 
fracture and time to first clinical nonvertebral fracture. This
trial was event-driven, so that it has been stopped after an interim
analysis has shown robust reduction in vertebral and hip fracture
incidence. The mean age at enrolment was 72 and 46% of these
women had at least one prevalent vertebral fracture. There was a
54% relative risk reduction of new and worsening morphometric
vertebral fractures, a 47% relative risk reduction of clinical hip
fractures, a 23% relative risk reduction of clinical nonvertebral
fractures and a 72% relative risk reduction of clinical vertebral
fractures. Interestingly, while there was a smaller reduction in
markers of bone resorption in comparison with other powerful
antiresorptive agents, the reduction in levels of formation mark-
ers was much smaller [56]. Furthermore, histomorphometry of
bone biopsies performed in a subset of 32 patients included in the
phase II trial showed that the modest reduction in bone formation
markers was not accompanied by a suppression of the bone for-
mation rate. These findings suggest a decoupling between bone
formation and resorption. It was hypothesised that as the inhibi-
tion of cathepsin K suppresses osteoclast function but does not
impair osteoclast viability, it may preserve the osteoclast-
osteoblast crosstalk and maintain bone formation [57]. In addi-
tion, unlike conventional antiresorptives, odanacatib displayed
site specific effects on trabecular versus cortical bone formation
with marked increases in periosteal bone formation and cortical
thickness in ovariectomised monkeys [58]. Although their clinical
relevance remains to be confirmed, these findings would repre-
sent a major advance in the field of bone research. A randomised,
placebo-controlled phase III fracture endpoint trial, which has
enrolled more than 16000 postmenopausal women with low bone
mass, is currently ongoing with expected results during summer
2012 (NCT00529373). Once available, the results of this study
will unveil a comprehensive efficacy and safety profile of
odanacatib for the treatment of postmenopausal osteoporosis [59,
60]. The US Food and Drug Administration (FDA) submission is
expected to occur in 2015 after gathering more follow-up data.
Conclusions
Denosumab is a fully human IgG2 antibody that binds to
RANK ligand with very high specificity. By preventing the interac-
tion of RANK ligand to its receptor RANK, denosumab is a potent
anti-resorptive agent, decreasing the formation, function, and sur-
vival of osteoclasts. Denosumab treatment of postmenopausal
women with low bone mass reduces bone remodeling and increas-
es bone mineral density (BMD). In women with postmenopausal
osteoporosis, denosumab therapy significantly reduced the risk of
new vertebral, hip, and nonvertebral fractures at 3 years compared
with placebo. This agent has received regulatory approval in many
countries for treating women with postmenopausal osteoporosis at
increased risk or high risk for fracture.
The concept of a therapy designed to target a critical enzyme
in the osteoclast bone resorption pathway is being translated into
a very interesting and attractive potential approach to the man-
agement of osteoporosis. Moreover, cathepsin K inhibition seems
to demonstrate a quality that is not present among other classes of
anti¬resorptive agent – namely greater suppression of bone
Fig. 2. Mean percentage change from baseline over time for the full-
analysis-set population in lumbar spine BMD (a) and femoral neck
BMD (b) at 5 years for three of the randomization groups. 50 mg,
odanacatib 50 mg once weekly; BMD, bone mineral density; PBO,
placebo once weekly; SE, standard error. (Adapted from [56])
resorption than of bone formation. These features make cathep-
sin K inhibition a very promising intervention with which to treat
osteoporosis. Despite initial difficul¬ties with the nonselective
nature of the early cathepsin K inhibitors, more-selective cathep-
sin K inhibition has reduced the potential for adverse events and
drug-drug interactions, at least so far. Further ongoing studies are
likely to shed more light on the long-term efficacy and safety of
prolonged treatment with odanacatib. In conclusion, odanacatib
is a cathepsin K inhibitor whose mechanism of action differs from
that of other antiresorptive agents. It does not reduce the number
of osteoclasts and does not alter their function, thereby offering
theoretical advantages over bisphosphonates. The results of the
phase III trial currently in development are required to confirm
these possible advantages.
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